Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy

Mitra, Amitava; Nan, Anjan; Papadimitriou, John C.; Ghandehari, Hamidreza; Line, Bruce R.

doi:10.1016/j.nucmedbio.2005.09.005

Cited by 65 publications

(58 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polyethyleneglycol in conjugation with camptothecin (EZ-246, Pegamotecan) (Posey et al 2005) and cyclodextrin in conjugation with camptothecin (Schluep et al 2006a, b;Zamboni et al 2006) are entering clinical trials. Polymer-drug conjugates are being directed not only against tumour cells, but also against angiogenic blood vessels, for example, HPMA-fumagillol (TNP-470) caplostatin (Satchi-Fainaro et al 2004;Huang et al 2004;Inoue et al 2003;Bhujwalla et al 2003), the HPMA copolymer-RGD4C-Tc-99m conjugate, capable of targeting tumour angiogenic vessels and delivering adequate radiotherapy to arrest tumour growth (Mitra et al 2006) and PEGylated cyclic arginine-glycine-aspartic acid (RGD) radiotracers (64-Cu-DOTAPEG-RGD and 125 I-RGD-mPEG) targeted at integrins (Chen et al 2004a, b). The emphasis in work on polymer-drug copolymers lies at present on drug delivery, but attachment of signal generators to these copolymeric nanoparticles is of considerable interest, because this would allow real-time monitoring of drug biodistribution and action.…”

Section: Polymersmentioning

confidence: 99%

Molecular imaging with nanoparticles: giant roles for dwarf actors

Debbage

Jaschke

2008

Histochem Cell Biol

233

212

View full text Add to dashboard Cite

Molecular imaging, first developed to localise antigens in light microscopy, now encompasses all imaging modalities including those used in clinical care: optical imaging, nuclear medical imaging, ultrasound imaging, CT, MRI, and photoacoustic imaging. Molecular imaging always requires accumulation of contrast agent in the target site, often achieved most efficiently by steering nanoparticles containing contrast agent into the target. This entails accessing target molecules hidden behind tissue barriers, necessitating the use of targeting groups. For imaging modalities with low sensitivity, nanoparticles bearing multiple contrast groups provide signal amplification. The same nanoparticles can in principle deliver both contrast medium and drug, allowing monitoring of biodistribution and therapeutic activity simultaneously (theranostics). Nanoparticles with multiple bioadhesive sites for target recognition and binding will be larger than 20 nm diameter. They share functionalities with many subcellular organelles (ribosomes, proteasomes, ion channels, and transport vesicles) and are of similar sizes. The materials used to synthesise nanoparticles include natural proteins and polymers, artificial polymers, dendrimers, fullerenes and other carbon-based structures, lipid-water micelles, viral capsids, metals, metal oxides, and ceramics. Signal generators incorporated into nanoparticles include iron oxide, gadolinium, fluorine, iodine, bismuth, radionuclides, quantum dots, and metal nanoclusters. Diagnostic imaging applications, now appearing, include sentinal node localisation and stem cell tracking.

show abstract

Section: Polymersmentioning

confidence: 99%

Molecular imaging with nanoparticles: giant roles for dwarf actors

Debbage

Jaschke

2008

Histochem Cell Biol

233

212

View full text Add to dashboard Cite

show abstract

“…Numerous types of targeting technology have been used to achieve these goals, with the peptide-based targeting vector technology becoming increasingly popular for diagnostic and therapeutic applications (3)(4)(5). Peptides have very good biocompatibility, limited immunogenicity in the body and non-specific uptake by the liver or the reticuloendothelial system (6).…”

Section: Introductionmentioning

confidence: 99%

In vitro assessment of the dual-targeting behavior of a peptide-based magnetic resonance imaging contrast agent

Yang

Zhang

et al. 2013

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Abstract. In this study, a peptide-based dual-targeting magnetic resonance imaging (MRI) contrast agent (S8) was designed and synthesized. Arg-Gly-Asp (RGD) and Asn-Gly-Arg (NGR) were combined in the targeting vector so as to allow binding, on the surface of tumor cells, to integrin α v β 3 and aminopeptidase N (CD 13 ), respectively. The longitudinal relaxivity (r 1 ) value of S8 was 8.297 mM -1 sec -1 at a magnetic field of 11.7 T, which is approximately double the r 1 value (4.25 mM -1 sec -1 ) of Magnevist, a commercially available contrast agent. MDA-MB-231 human breast cancer cells (which overexpress α v β 3 ) and human prostate cancer cells PC-3 (which overexpress CD 13 ) were used to investigate the tumor-targeting behavior of S8. The results from the present study indicate that the designed contrast agent, S8, targets both MDA-MB-231 and PC-3 cells.

show abstract

“…The humanized monoclonal antibody bevacizumab, directed against vascular endothelial growth factor (VEGF), is the first and currently the only anti-angiogenic agent to be approved for cancer therapy [1]. Approval of bevacizumab was based on the results of several crucial phase II and III studies in patients with previously untreated metastatic CRC [6]. The antibody is currently scrutinized in at least 11 clinical case studies (Phase I-III) for various cancers as per information available from the dedicated avastin website.…”

Section: -6-biodistribiotion Studiesmentioning

confidence: 99%

Anti-Angiogenesis Therapy of Cancer Cells using 153Sm-Bevasesomab

Yavari¹

2018

ESJ

View full text Add to dashboard Cite

Purpose: Angiogenesis is essential for tumor growth or metastasis. Avastin is a monoclonal antibody that is used in treating angiogenesis. We labelled this monoclonal antibody with samarium153 and performed in vitro quality control tests as a first step in the production of a new radiopharmaceutical.Material and Methods: For a successful radiolabeling, we chose DOTA-NHS as the bifunctional chelating agent and optimized radiolabeling condition with modifications of the factors such as reaction time and molar ratio which are known to be very critical in radiolabeling. The efficiency and in vitro stability of antibody labelling were determined using thin layer chromatography. The integrity of the radiolabeled antibody was checked by SDS-PAGE. Biodistribution study of 153Sm-DOTA -avastin was carried out in BALB/c mice at 2, 24, 48 and 72 hours after injection. Immunoreactivity and toxicity of the complex were tested on colon cancer cell line by MTT.Results: The efficiency of antibody labelling was more than 99%. The in vitro stability of the labelled product in human serum after 120h was 78 ±2%. There was no fragmentation in the labelled antibody during SDS-PAGE protocol. The highest of %ID/g was observed in the blood, liver, lungs and spleen. The immunoreactivity of the complex was 89±1.4%. At a concentration of 1 nM, the complex killed 70±3% of SW480 cells. At 1.9 nM, 90±5% of the cells were killed.Discussion: The monoclonal antibody avastin against angiogenesis was effectively radiolabeled with 153Sm. The results showed that the new complex could be considered a promising tracer for noninvasive delineation of angiogenesis.

show abstract

Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy

Cited by 65 publications

References 27 publications

Molecular imaging with nanoparticles: giant roles for dwarf actors

Molecular imaging with nanoparticles: giant roles for dwarf actors

In vitro assessment of the dual-targeting behavior of a peptide-based magnetic resonance imaging contrast agent

Anti-Angiogenesis Therapy of Cancer Cells using 153Sm-Bevasesomab

Contact Info

Product

Resources

About